Nowadays, the clinical diagnosis of AD is based on cognitive measures and one or more biomarkers including structural MRI, PET, and cerebrospinal fluid analysis of amyloid β or tau proteins (Bruno et al., 2007). The gene discussed is MAPT; the disease is Alzheimer disease.